More than 1,200 employees across the U.S., Europe, and Japan unite to support multiple organizations during annual company-wide day of service BRIDGEWATER, N.J. , Nov. 13, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today...
During the quarter, we initiated new positions in Spotify, L3Harris Technologies and Insmed. We also added to 3i Group, West Pharmaceutical and Amazon during the quarter. We ended our investment campaigns in Atlassian, Adidas and Vertex Pharmaceuticals during the quarter.
Google's parent company received a relatively benign antitrust ruling that would not force Alphabet to sell its Chrome browser or Android operating system. Alnylam's shares benefited from a positive phase 3 trial by Regeneron Pharmaceuticals that uses Alnylam's technology. We initiated a position in AppLovin, the only scaled, global advertisement network for gaming properties.
BRIDGEWATER, N.J. , Nov. 5, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that management will present at the following investor conferences: Jefferies Global Healthcare Conference in London, on Tuesday, Nov...
Insmed Incorporated ( INSM ) Q3 2025 Earnings Call October 30, 2025 8:00 AM EDT Company Participants Bryan Dunn - Vice President of Investor Relations William Lewis - President, CEO & Chairman Roger Adsett - Chief Operating Officer Sara Bonstein - Chief Financial Officer Martina Flammer - Chief Medical Officer Conference Call Participants Jessica Fye - JPMorgan Chase & Co, Research Division Rit...
—BRINSUPRI ™ (brensocatib ) Approved by FDA as First and Only Treatment for Non-Cystic Fibrosis Bronchiectasis; Positive CHMP Opinion Adopted in the European Union and Application Accepted in Japan— —BRINSUPRI Total Revenue of $ 28.1 Million for the Third Quarter of 2025— —ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $ 114.3 Million for the Third Quarter of 2025, Reflect...
Argenx SE is a biotechnology company best known for developing Vyvgart, the leading FcRn inhibitor for the treatment of autoimmune conditions. RadNet, Inc. is the largest operator of outpatient diagnostic imaging services and related solutions in the U.S. Intuitive Surgical, Inc. manufactures the da Vinci Surgical System, a robotic surgical system used for minimally invasive surgical procedures.
—Insmed Leads Science Top Employers List for Fifth Year in a Row— BRIDGEWATER, N.J. , Oct. 23, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that it has earned the highest ranking in Science's 2025 Top Emplo...
Kostenlos registrieren
aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.